Our Partnerships Make All the Difference

We believe developing collaborations and partnerships is a key part of our strategy to successfully leveraging our portfolio of therapeutic products and platform technologies.

Current Partners

In January 2013, we entered into a collaboration agreement with Algeta ASA, for the development of epratuzumab conjugated with Algeta’s proprietary thorium-227 alpha-pharmaceutical payload.

Clinical Programs for Partnering

Technology Partnering Opportunity

Patent Portfolio

We have accumulated an extensive patent portfolio in the course of our research in the areas of Multivalent Bispecific Antibodies, F-18 Labeling, DOCK-AND-LOCKā„¢, Antibody-Drug Conjugates, Antibody-Drug Conjugate Linker, and T-cell Redirecting Antibodies, which we believe constitutes a very valuable business asset.

Learn More